Ajay Babu Pazhayattil.

Since 2019, Dr. Pazhayattil has advised pharmaceutical manufacturers as an independent consultant, frequently working alongside regulatory consultants and legal counsel. He has led U.S. FDA warning letter remediation programs for finished drug products across injectable, solid oral, semi-solid, and oral liquid dosage forms, as well as at active pharmaceutical ingredient (API) manufacturing facilities. In that work, he brings newly developed and legacy products and processes into alignment with current regulatory expectations while maintaining U.S. market supply. He has directed manufacturers’ responses to FDA Form 483 observations and warning letters. His experience also includes independent quality oversight and consulting leadership in validation, metrology, and qualification programs for pharmaceutical manufacturing and filling lines. As a subject matter expert, he has prepared independent technical assessments and contamination risk evaluations for complex pharmaceutical manufacturing matters.

Before establishing his independent consulting practice, Dr. Pazhayattil spent six years at Apotex as Associate Director of Technical Operations, where he led process validation and continued process verification across multiple sites, established an applied statistics department, and served as a subject matter expert during U.S. FDA, Health Canada, and EMA inspections. He directed quality at Eurofins CDMO and served as Vice President of QA Compliance at Capcium, leading the organization through its first successful U.S. FDA inspection. Earlier in his career, he held quality, validation, and regulatory positions at Patheon (now Thermo Fisher), Pharmetics, Wellspring (Shire), NBTY (Leiner Health), Marcan, and Intas.

Dr. Pazhayattil has contributed to pharmaceutical technical publications and guidance documents developed by the International Society for Pharmaceutical Engineering (ISPE), the American Association of Pharmaceutical Scientists (AAPS), the Regulatory Affairs Professionals Society (RAPS), and the Parenteral Drug Association (PDA). He has published more than 75 articles, including over 28 peer-reviewed scientific journal articles. He holds a Doctorate in Business Administration from California Southern University, where his research examined machine learning and AI adoption in pharmaceutical manufacturing, and a Master of Pharmacy (M.Pharm.) from Rajiv Gandhi University of Health Sciences. He is an ASQ Certified Pharmaceutical GMP Professional.